Roche Fenebrutinib FDA Filing Accepted Under Priority Review for Relapsing and Primary Progressive Multiple Sclerosis.
The Roche fenebrutinib FDA filing has been accepted under priority review for relapsing and primary progressive multiple sclerosis. The application draws on the FENhance 1, FENhance 2 and FENtrepid Phase III studies.
